ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora ...

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora ...

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. ("Clearside" or the "Company") (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111, ...

Yi Chen - H.C. Wainwright Jenny Kobin In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change. Thanks, Jenny, and good afternoon, everyone. Today, I'm excited to discuss several recent value creating achievements related to our suprachoroidal platform. We've ...

Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, the accounting for useful lives to calculate ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q2 2023 Results Conference Call August 14, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Jon Wolleben - JMP Securities Shawn Kim - Jones Trading Rohit Bhasin - Needham & Company I will now turn the conference over to your host, Jenny Kobin of Investor Relations. You may begin. Good afternoon, everyone, and thank you for joining us on the call today. Jack Padavano - Stifel Yi Chen - H.C. ...

FORM 10-Q | --- | --- | |------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | Clearside Biomedical, \n(Exact Name of Registrant as \nDelaware | Inc. \nSpecified in its Charter) \n45-2437375 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 900 North Point Parkway, Suite 200 Alpharetta, GA (Address of principal executive offices) | ...

Serge Belanger Annabel Samimy George Lasezkay Annabel Samimy So just, I want to make sure we're clear with that. What the good the endpoints have necessarily changed as we go into Phase 3. But you're just looking right now at treatment burden. But for our Phase 2 trial, for our Phase 2 trial, we're looking at treatment burden and we're looking at duration as I said to set up the best design possible to go into Phase 3 with a fixed dosing schedule of CLS-AX, and obviously going to phase 3, unless the draft g ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ In ...

Novel SCS Microinjector® shows a demonstrated ability for precise delivery into the suprachoroidal space SCS injection procedure commercially accepted by retinal physicians following launch of XIPERE® • Thousands of SCS injections performed Safety profile comparable to intravitreal injections1 • No Serious Adverse Events (SAEs) involving lens injury, suprachoroidal hemorrhage, or endophthalmitis have been observed 6 clinical trials ongoing including partner programs Sources: Clearside data on file | 1Kurup, ...